You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Retrofittable and Transparent Super-Insulator for Single-Pane Windows

    SBC: NANOSD, INC.            Topic: DEFOA0001429

    NanoSD, Inc. with its partners will develop a transparent, nanostructured thermally insulating film that can be applied to existing single-pane windows to reduce heat loss. To produce the nanostructured film, the team will create hollow ceramic or polymer nanobubbles and consolidate them into a dense lattice structure using heat and compression. Because it is mostly air, the resulting nanobubble s ...

    STTR Phase II 2016 Department of EnergyARPA-E
  2. Breakthrough sub cellular D chemical composition research platform for live cells based on the new invention of nanoscale confocal photothermal IR micro spectroscopy n CPIR

    SBC: Anasys Instruments Corp.            Topic: 100

    Abstract This proposal will lead to a Breakthrough sub cellular D chemical composition research platform for live cells based on the new invention of sub micron confocal photothermal IR micro spectroscopy CPIR Label free sub micron chemical imaging and spectroscopy has long been sought for visualization of biomolecules and materials in complex living systems Many diseases first manifest ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Automated Electrophysiology Assessment of Drug induced Cardiotoxicity Based on Parallel Noninvasive Nanoelectrode Array

    SBC: CYION TECHNOLOGIES LLC            Topic: NIBIB

    Summary Drug safety issues pose a serious challenge to the health and well being of patients The development of our innovative technology aims to address a significant gap in the in vitro assessment of drug induced cardiotoxicity which is the number one reason for withdrawals of all marketed drugs as well as the premature termination of promising drug development candidates Pressured by the eno ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Commercialization of a Novel Therapeutic for Alzheimer's Disease

    SBC: CoPlex Therapeutics, LLC            Topic: NIA

    ABSTRACT Traditional mon therapeutictarget driven approaches to drug development for Alzheimer s diseaseADare becoming increasingly expensive and in many cases disappointingly unsuccessfulBased on preliminary in vitro and in vivo studies we have identified a novel small moleculemethyldimethyloxodihydrobenzo cnaphthyridinecarboxylateBNCthat significantly decreases neuroinflammation and production o ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Treatment for Traumatic Brain Injury

    SBC: Epigen Biosciences, Inc.            Topic: 101

    SUMMARY Traumatic brain injury TBI is a leading contributor to death and disability in the USA yet widely effective treatments remain elusive and except for a lengthy program of rehabilitation no effective treatment for TBI is available Therefore there is a critical need in new therapeutic approaches which can maximally preserve brain tissue and facilitate functional recovery after TBI In ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Pirenzepine for HIV SN

    SBC: WinSanTor, Inc.            Topic: 101

    PROJECT SUMMARY Over million people worldwide including million people in the USA are HIV positive HIV associated sensory neuropathy HIV SN is the most frequent neurological manifestation of HIV and is characterized as a distal symmetrical predominantly sensory polyneuropathy HIV SN may represent clinically indistinguishable neuropathies with distinct pathogenesis a distal axona ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Novel therapy for Fragile X syndrome

    SBC: Epigen Biosciences, Inc.            Topic: 101

    PROJECT SUMMARY Fragile X syndromeFXSis the most common inheritable form of cognitive impairment and the leading known genetic cause of autismFXS is caused by the loss of expression of the fragile X mental retardation proteinFMRPA major challenge for FXS research is to develop treatment strategies that improve the intellectual capabilities of patientsDysregulated protein synthesis is widely accept ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Comprehensive Glycoproteomic Tool Development for Cancer Biomarkers

    SBC: Protein Metrics Inc.            Topic: 400

    Project SummaryGlycosylation is one of the most prevalent and important post translational modifications of proteinsyet it is also one of the most difficult to studyNo single method nor analytical platform can give complete information about the glycosylation in a protein sampleand the analytical methods in current use include both ESI and MALDI single and tandem mass spectrometryat least four typ ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a new small molecule therapeutic for the treatment of resistant breast cancer

    SBC: VioMedix, LLC            Topic: 102

    PROJECT SUMMARYABSTRACTBreast cancer is the second leading cause of death in females with cancerInapproximatelynew cases of invasive breast cancer were diagnosedwhere an estimate ofwas expected to succumb to their diseaseIt is estimated that one in eight women will develop breast cancer in their lifetimeBreast cancer is classified into subtypes based on the expression of estrogen receptorERprogest ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Skin Microbiome Editing with Fermentation Initiator

    SBC: Surface Bioadvances, Inc.            Topic: NIAMS

    Abstract Acne dysbiosis is defined as microbial imbalance with the over growth of Propionibacterium acnes P acnes in the acne microbiome We have demonstrated that Staphylococcus epidermidis S epidermidis a probiotic bacterium co existed with P acnes in an acne lesion can exploit the carbohydrate fermentation to produce short chain fatty acids SCFAs and rein in the over growth of P ac ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government